On the early toxic effect of quinolinic acid: Involvement of RAGE

Neuroscience Letters

Volumn 474, Issue 2, 2010, Pages 74-78

  Cuevas, Elvis ^a,b   Lantz, Susan ^b   Newport, Glenn ^b   Divine, Becky ^b   Wu, Qiangen ^b   Paule, Merle G ^b   Tobón Velasco, J César ^a   Ali, Syed F ^b   Santamaría, Abel ^a,b  

^a NATIONAL INSTITUTE OF NEUROLOGY AND NEUROSURGERY   (Mexico)

^b NATIONAL CENTER FOR TOXICOLOGICAL RESEARCH   (United States)

Author keywords

Huntington's disease; Neurodegeneration; Neurotoxicity; NF B; Oxidative stress; Quinolinic acid; Receptor for advanced glycation end products

Indexed keywords

ADVANCED GLYCATION END PRODUCT RECEPTOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LACTATE DEHYDROGENASE; NITRIC OXIDE; QUINOLINIC ACID;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CORPUS STRIATUM; MALE; NEUROTOXICITY; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; RAT; RECEPTOR UPREGULATION;

ANIMALS; CORPUS STRIATUM; CYCLOOXYGENASE 2; GENE EXPRESSION REGULATION; GLIAL FIBRILLARY ACIDIC PROTEIN; INDOLES; L-LACTATE DEHYDROGENASE; MALE; NEUROTOXINS; NITRATES; PROTEIN-SERINE-THREONINE KINASES; QUINOLINIC ACID; RANDOM ALLOCATION; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, IMMUNOLOGIC; SPECTROPHOTOMETRY; SUPEROXIDE DISMUTASE;

EID: 77951258749     PISSN: 03043940     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neulet.2010.03.007     Document Type: Article

References (38)

1. Aguilera P., Chánez-Cárdenas M.E., Floriano-Sánchez E., Barrera D., Santamaría A., Sánchez-González D.J., Pérez-Severiano F., Pedraza-Chaverrí J., Jiménez P.D. Time-related changes in constitutive and inducible nitric oxide synthases in the rat striatum in a model of Huntington's disease. Neurotoxicology 2007, 28:1200-1207.
2. Alves M., Calegari V.C., Cunha D.A., Saad M.J., Velloso L.A., Rocha E.M. Increased expression of advanced glycation end-products and their receptor, and activation of nuclear factor kappa-B in lacrimal glands of diabetic rats. Diabetologia 2005, 48:2675-2681.
3. Borlongan C.V., Koutouzis T.K., Sanberg P.R. 3-Nitropropionic acid animal model and Huntington's disease. Neurosci. Biobehav. Rev. 1997, 21:289-293.
4. Chen X., Walker D.G., Schmidt A.M., Arancio O., Lue L.F., Yan S.D. RAGE: a potential target for Abeta-mediated cellular perturbation in Alzheimer's disease. Curr. Mol. Med. 2007, 7:735-742.
5. Ding Q., Keller J.N. Evaluation of RAGE isoforms, ligands, and signaling in the brain. Biochim. Biophys. Acta 2005, 1746:18-27.
6. González-Cortés C., Salinas-Lara C., Gómez-López M.A., Tena-Suck M.L., Perez-De la Cruz V., Rembao-Bojorquez D., Pedraza-Chaverri J., Gomez-Ruiz C., Galvan-Arzate S., Ali S.F., Santamaria A. Iron porphyrinate Fe(TPPS) reduces brain cell damage in rats intrastriatally lesioned by quinolinate. Neurotoxicol. Teratol. 2008, 30:510-519.
7. Guidetti P., Luthi-Carter R.E., Augood S.J., Schwarcz R. Neostriatal and cortical quinolinate levels are increased in early grade Huntington's disease. Neurobiol. Dis. 2004, 7:455-461.
8. Hammes H.P., Hoeauf H., Alt A., Schleicher E., Clausen J.T., Bretze R.G., Lagua H. N(epsilon)(carboxymethyl)lysine and the AGE receptor RAGE colocalize in age-related macular degeneration. Invest. Ophtalmol. Vis. Sci. 1999, 40:1855-1859.
9. Heizmann C.W., Ackermann G.E., Galichet A. Pathologies involving the S100 proteins and RAGE. Subcell. Biochim. 2007, 45:93-138.
10. Li W., Khor T.O., Xu C., Shen G., Jeong W.S., Yu S., Kong A.N. Activation of Nrf2-antioxidant signaling attenuates NFkappaB-inflammatory response and elicits apoptosis. Biochem. Pharmacol. 2008, 76:1485-1489.
11. Liu X., Luo D., Zheng M., Hao Y., Hou L., Zhang S. Effect of pioglitazone on insulin resistance in fructose-drinking rats correlates with AGEs/RAGE inhibition and block of NAPDH oxidase and NF kappa B activation. Eur. J. Pharmacol. 2010, 629:153-158.
12. Lue L.F., Yan S.D., Stern D.M., Walker D.G. Preventing activation of receptor for advanced glycation endproducts in Alzheimer's disease. Curr. Drug Targets CNS Neurol. Disord. 2005, 4:249-266.
13. Ma L., Nicholson L.F.B. Expression of the receptor for advanced glycation end products in Huntington's disease caudate nucleus. Brain Res. 2004, 1018:10-17.
14. Maldonado P.D., Chánez-Cárdenas M.E., Barrera D., Villeda-Hernandez J., Santamaria A., Pedraza-Chaverri J. Poly(ADP-ribose) polymerase-1 is involved in the neuronal death induced by quinolinic acid in rats. Neurosci. Lett. 2007, 425:28-33.
15. Maldonado P.D., Molina-Jijón E., Villeda-Hernández J., Galvan-Arzate S., Santamaria A., Pedraza-Caverri J. NAD(P)H oxidase contributes to neurotoxicity in an excitotoxic/pro-oxidant model of Huntington's disease in rats: protective role of apocynin. J. Neurosci. Res. 2010, 88:620-629.
16. Miller M.C., Tavares R., Johanson C.E., Hoanesian V., Donaue J.E., Gonzalez L., Silverberg G.D., Stopa E.G. Hippocampal RAGE immunoreactivity in early and advanced Alzheimer's disease. Brain Res. 2008, 1230:273-280.
17. Münch G., Thome J., Foley P., Schinzel R., Riederer P. Advanced glycation end-products in ageing and Alzheimer's disease. Brain Res. Rev. 1997, 23:134-143.
18. Onyango I.G., Tuttle J.B., Bennett J.P. Altered intracellular signaling and reduced viability of Alzheimer's disease neuronal cybrids is reproduced by β-amyloid peptide acting through receptor for advanced glycation end products (RAGE). Mol. Cell Neurosci. 2005, 29:333-343.
19. Paxinos G., Watson C. The Rat Brain in Stereotaxic Coordinates 1998, Academic Press, San Diego.
20. Pérez-De La Cruz V., González-Cortés C., Galván-Arzate S., Medina-Campos O.N., Pérez-Severiano F., Ali S.F., Pedraza-Chaverrí J., Santamaría A. Excitotoxic brain damage involves early peroxynitrite formation in a model of Huntington's disease in rats: protective role of iron porphyrinate Fe (TPPS). Neuroscience 2005, 135:463-474.
21. Pérez-Severiano F., Rodríguez-Pérez M., Pedraza-Chaverrí J., Maldonado P.D., Medina-Campos O.N., Ortiz-Plata A., Sanchez-Garcia A., Villeda-Hernandez J., Galva-Arzate S., Aguilera P., Santamaría A. S-allylcysteine, a garlic-derived antioxidant, ameliorates quinolinic acid-induced neurotoxicity and oxidative damage in rats. Neurochem. Int. 2004, 45:1175-1183.
22. Rodríguez-Martínez E., Camacho A., Maldonado P.D., Pedraza-Chaverrí J., Santamaría D., Galván-Arzate S., Santamaría A. Effect of quinolinic acid on endogenous antioxidants in rat corpus striatum. Brain Res. 2000, 858:436-439.
23. Roehm N.W., Rodgers G.H., Hatfield S.M., Gaserbrook A.L. An improved colorimetric assay for cell proliferation and viability utilizing the tetrazolium salt XTT. J. Immunol. Methods 1991, 142:257-265.
24. Salminen A., Ojala J., Kauppinen A., Kaarniranta K., Suuronen T. Inflammation in Alzheimer's disease: amyloid-beta oligomers trigger innate immunity defence via pattern recognition receptors. Prog. Neurobiol. 2009, 87:181-194.
25. Santamaría A., Jiménez M.E. Oxidative/nitrosative stress, a common factor in different neurotoxic paradigms: an overview. Curr. Top. Neurochem. 2005, 4:1-20.
26. Santamaría A., Jiménez-Capdeville M.E., Camacho A., Rodriguez-Martinez E., Flores A., Galvan-Arzate S. In vivo hydroxyl radical formation after quinolinic acid infusion into rat corpus striatum. Neuroreport 2001, 12:2693-2696.
27. Santamaría A., Ríos C. MK-801, an N-methyl-d-aspartate receptor antagonist, blocks quinolinic acid-induced lipid peroxidation in rat corpus striatum. Neurosci. Lett. 1993, 159:51-54.
28. Santamaría A., Salvatierra-Sánchez R., Vázquez-Román B., Santiago-Lopez D., Villeda-Hernandez J., Galvan-Arzate S., Jimenez-Capdevlle M.E., Ali S.F. Protective effects of the antioxidant selenium on quinolinic acid-induced neurotoxicity in rats: in vitro and in vivo studies. J. Neurochem. 2003, 86:479-488.
29. Santamaría A., Vázquez-Román B., Pérez-De La Cruz V., Gozalez-Cortes C., Trejo-Solis M.C., Galvan-Arzate S., Jara-Prado A., Guevara-Fonseca J., Ali S.F. Selenium reduces the pro-apoptotic signaling associated to NFkB pathways and stimulates glutathione peroxidase activity during excitotoxic damage produced by quinolinate in rat corpus striatum. Synapse 2005, 58:258-266.
30. Schwarcz R., Guidetti P., Sathyasaikumar K.V., Muchowski P.J. Of mice, rats and men: Revisiting the quinolinic acid hypothesis of Huntington's disease, Prog. Prog. Neurobiol. 2010, 90:230-245.
31. Silva-Adaya D., Pérez-De La Cruz V., Herrera-Mundo M.N., Mendoza-Macedo K., Villeda-Hernandez J., Binienda Z., Ali S.F., Santamaria A. Excitotoxic damage, disrupted energy metabolism, and oxidative stress in the rat brain: antioxidant and neuroprotective effects of l-carnitine. J. Neurochem. 2008, 105:677-689.
32. V. Srikanth, A. Maczurek, T. Phan, et al., Advanced glycation endproducts and their receptor RAGE in Alzheimer's disease. Neurobiol. Aging, doi:10.1016/j.neurobiolaging.2009.04.016.
33. Stone T.W., Darlington L.G. Endogenous kynurenines at targets for drug discovery and development. Nat. Rev. Drug Discov. 2002, 1:609-620.
34. Takeuchi M., Yamagishi S. Possible involvement of advanced glycation end-products (AGEs) in the pathogenesis of Alzheimer's disease. Curr. Pharm. Des. 2008, 14:973-978.
35. Tasset I., Pérez-De La Cruz V., Elinos-Calderón D., Carrillo-Mora P., Gonzalez-Herrera I.G., Luna-Lopez A., Konigsberg M., Pedraza-Chaverri J., Maldonado P.D., Ali S.F., Tunez I., Santamaria A. Protective effect of tert-butylhydroquinone on the quinolinic acid-induced toxicity in rat striatal slices: role of the Nrf2-ARE pathway. Neurosignals 2010, 18:24-31.
36. Titheradge M.A. The enzymatic measurement of nitrate and nitrite. Methods in Molecular Biology 1997, 83-91. Humana Press Inc, Totowa, NJ, Chapter 9. M.A. Titheradge (Ed.).
37. Toth C., Martínez J., Zochodne D.W. RAGE, diabetes, and the nervous system. Curr. Mol. Med. 2007, 7:766-776.
38. Zlokovic B.V. New therapeutic targets in the neurovascular pathway in Alzheimer's disease. Neurotherapeutics 2008, 5:409-414.